4594 BrightPath Biotherapeutics Co., Ltd. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4594

TSE Growth

BrightPath Biotherapeutics Co., Ltd.

JPY

(0.00%)

Dec 23, 3:30 pm JST

0.28

USD

Dec 23, 1:30 am EST

Result

PTS

outside of trading hours

44.3

Dec 23, 7:50 pm JST

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2021	2	-1,732	-1,738	-1,719	-36.1	0	May 13, 2021	J-GAAP
Mar, 2022	15	-1,476	-1,481	-1,484	-28.6	0	May 12, 2022	J-GAAP
Mar, 2023	5	-1,467	-1,473	-1,485	-24.9	0	May 12, 2023	J-GAAP
Mar, 2024	0	-1,155	-1,158	-1,168	-18.2	0	May 10, 2024	J-GAAP
Mar, 2025 Guidance	0	-925	-925	-927	-10.7	0	May 10, 2024	J-GAAP
YoY	－	+19.9%	+20.1%	+20.6%	+41.3%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Mar, 2020	May 10, 2019	4	-2,417	-2,417	-2,437	0	J-GAAP
	Jan 17, 2020	11	-2,417	-2,417	-2,437	0	J-GAAP
Results	May 15, 2020	11	-1,827	-1,823	-1,857	0	J-GAAP
Mar, 2021	May 15, 2020	Available in future release
Results	May 13, 2021
Mar, 2022	May 13, 2021
	Mar 30, 2022
Results	May 12, 2022
Mar, 2023	May 12, 2022
Results	May 12, 2023
Mar, 2024	May 12, 2023
	Jan 26, 2024
Results	May 10, 2024
Mar, 2025	May 10, 2024	0	-925	-925	-927	0	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Mar, 2011	117	－	Available in future release
Mar, 2012	194	+65.8
Mar, 2013	451	+132.5
Mar, 2014	933	+106.9
Mar, 2015	821	-12.0
Mar, 2016	822	+0.1
Mar, 2017	529	-35.6
Mar, 2018	354	-33.1
Mar, 2019	155	-56.2
Mar, 2020	11	-92.9
Mar, 2021	2	-81.8
Mar, 2022	15	+650.0
Mar, 2023	5	-66.7
Mar, 2024	0	-100.0
Mar, 2025 Guidance	0	－	-925	+19.9	-925	+20.1	-10.7	+41.2

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Mar, 2023	5	-1,467	-29,340	-73.24	-66.41	ー	-24.9
Mar, 2024	0	-1,155	ー	-93.33	-79.70	ー	-18.2
Mar, 2025 Guidance	0	-925	ー	-76.55	-54.66	ー	-10.7

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	933	-27	219	217	1,821.9
Fiscal Year	Mar, 2014	Mar, 2014	Mar, 2013	Mar, 2013	Mar, 2013

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2021	15	-755	-758	-761	-14.6	0	May 12, 2022	J-GAAP
Oct - Mar, 2022	5	-662	-664	-675	-11.3	0	May 12, 2023	J-GAAP
Oct - Mar, 2023	0	-605	-607	-615	-9.6	0	May 10, 2024	J-GAAP
Oct - Mar, 2024 Guidance	0	-383	-388	-389	-4.5	0	Nov 8, 2024	J-GAAP
YoY	－	+36.7%	+36.1%	+36.7%	+53.2%

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Mar, 2022	-1,476	-1,529	-1,512	-17	569	2,305	83.18	J-GAAP
Mar, 2023	-1,467	-1,205	-1,204	-1	432	1,530	89.95	J-GAAP
Mar, 2024	-1,155	-1,163	-1,156	-7	690	1,057	85.93	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 2nd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Sep, 2022	0	-805	-809	-810	-14.2	ー	Nov 11, 2022	J-GAAP
Apr - Sep, 2023	0	-550	-551	-553	-8.8	ー	Nov 10, 2023	J-GAAP
Apr - Sep, 2024	0	-542	-537	-538	-7.1	ー	Nov 8, 2024	J-GAAP
YoY	－	+1.5%	+2.5%	+2.7%	+19.3%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2022	5	-413	-414	-415	-7.1	-8,260.0	Feb 10, 2023	J-GAAP
Jan - Mar, 2023	0	-249	-250	-260	-4.4	-Inf	May 12, 2023	J-GAAP
Apr - Jun, 2023	0	-293	-293	-295	-4.7	-Inf	Aug 10, 2023	J-GAAP
Jul - Sep, 2023	0	-257	-258	-258	-4.1	-Inf	Nov 10, 2023	J-GAAP
Oct - Dec, 2023	0	-397	-396	-400	-6.4	-Inf	Feb 9, 2024	J-GAAP
Jan - Mar, 2024	0	-208	-211	-215	-3.4	-Inf	May 10, 2024	J-GAAP
Apr - Jun, 2024	0	-326	-329	-330	-4.7	-Inf	Aug 9, 2024	J-GAAP
Jul - Sep, 2024	0	-216	-208	-208	-2.8	-Inf	Nov 8, 2024	J-GAAP
YoY	－	+16.0%	+19.4%	+19.4%	+33.1%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Oct - Dec, 2019	1	-91.7	Available in future release
Jan - Mar, 2020	9	+800.0
Apr - Jun, 2020	0	－
Jul - Sep, 2020	1	0.0
Oct - Dec, 2020	0	-100.0
Jan - Mar, 2021	1	-88.9
Apr - Jun, 2021	0	－
Jul - Sep, 2021	0	-100.0
Oct - Dec, 2021	0	－
Jan - Mar, 2022	15	+1,400.0
Apr - Jun, 2022	0	－
Jul - Sep, 2022	0	－
Oct - Dec, 2022	5	－
Jan - Mar, 2023	0	-100.0
Apr - Jun, 2023	0	－
Jul - Sep, 2023	0	－
Oct - Dec, 2023	0	-100.0
Jan - Mar, 2024	0	－
Apr - Jun, 2024	0	－
Jul - Sep, 2024	0	－	-216	+16.0	-208	+19.4	-2.8	+31.7

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	209	-180	-190	-190	-2.8
Fiscal Year	Sep, 2015	Dec, 2015	Jun, 2016	Jun, 2016	Sep, 2024

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Mar, 2022	45.40	90.5	2,771	2,508	-10,875	0.03	May 12, 2022	J-GAAP
Mar, 2023	24.60	90.9	1,701	1,547	-1,485	ー	May 12, 2023	J-GAAP
Mar, 2024	13.52	77.7	1,230	956	-2,653	0.12	May 10, 2024	J-GAAP
Apr - Sep, 2024	ー	71.4	1,696	1,211	-3,192	0.27	Nov 8, 2024	J-GAAP

BrightPath Biotherapeutics Co., Ltd.(4594) Financial Results